Merck Buys Bio-Techne
Merck agrees to buy Bio-Techne for $73 per share in cash, valuing the company at an enterprise value of $11.3 billion.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.